

Erratum

Downregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTEN: Am J Transl Res. 2017; 9(4): 1886-1895

Xiang Xia, Kundong Zhang, Guangtao Luo, Gang Cen, Jun Cao, Kejian Huang, Zhengjun Qiu

Department of General Surgery, Shanghai General Hospital/First People's Hospital, Shanghai Jiaotong University, No. 100 Haining Road, Shanghai 200080, China

Received July 23, 2022; Accepted January 2, 2025; Epub May 15, 2025; Published May 30, 2025

In this article, a mistake was found where in **Figure 4D** a western blot image was falsely placed. Therefore, we are publishing this Erratum to reflect this change. The error has no bearing on the interpretation of the results, nor does it influence the conclusions of this work. We sincerely apologize for any inconvenience caused. The corrected **Figure 4** is as follows.

Address correspondence to: Kejian Huang and Zhengjun Qiu, Department of General Surgery, Shanghai General Hospital/First People's Hospital, Shanghai Jiaotong University, No. 100 Haining Road, Shanghai 200080, China. E-mail: huangkjmd@163.com (KJH); Tel: +86-13651810863; E-mail: qiuzjdoctor@sina.com (ZJQ)

The role of miR-301a-3p in gemcitabine treatment




Figure 4. PTEN was a direct target of miR-301a-3p in panc-1 cells. (A) Schematic graph of the putative binding sites of miR-301a-3p in the PTEN 3'UTR. The PTEN mutant had a mutated 3'UTR to prevent miR-301a-3p binding. (B) Treatment with miR-301a-3p decreased the luciferase reporter activity of the wild-type PTEN 3'UTR (** $P < 0.01$ versus the control) but not that of the mutant PTEN 3'UTR. (C, D) Levels of PTEN mRNA and protein in panc-1 cells after transfection with nonspecific-oligonucleotide control, miR-301a-3p mimic, or miR-301a-3p inhibitor examined by qRT-PCR (C) and Western blot (D), * $P < 0.05$ versus the control.